Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2

Circulation. 2023 Jan 17;147(3):276-279. doi: 10.1161/CIRCULATIONAHA.122.061688. Epub 2023 Jan 17.

¹ Laboratory of Experimental Intensive Care and Anesthesiology, Department of Anesthesiology (S.C., Q.W., D.B., M.W.H.., N.C.W., C.J.Z.), Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, the Netherlands.
² Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Greece (A.C., N.M., I.A.).
³ Institut für Herz- und Kreislaufphysiologie, Medizinische Fakultät und Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Germany (R.N.).
⁴ Department of Experimental Cardiology (R.C.), Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, the Netherlands.
⁵ Department of Medical Biology (V.W., V.M.C.), Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, the Netherlands.

^# Contributed equally.

No abstract available

Keywords: body weight; empagliflozin; glucose; infarct size; ischemia/reperfusion; ketones; sodium-glucose cotransporter 2 inhibitor.

Publication types